Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES news (Ticker: RTGN), a resource for investors and traders seeking the latest updates and insights on RETINALGENIX TECHNOLOGIES stock.
RetinalGenix Technologies Inc. (RTGN) is an ophthalmic research and development company whose news flow centers on high-resolution retinal imaging, genetic screening, and therapeutic programs for ocular and systemic diseases. Company announcements describe a developmental-stage business working at the intersection of retinal imaging, DNA/RNA/GPS Pharmaco-Genetic Mapping™, and drug development for conditions such as dry age-related macular degeneration, Alzheimer’s disease/dementia, and other neurodegenerative and metabolic disorders.
News releases frequently highlight progress on investigational imaging platforms, including the RetinalCam™ remote monitoring system and home and remote ocular monitoring technologies covered by patents. Updates have described prototype imaging systems that are imaging patients, patent grants for real-time home monitoring and physician alert workflows, and the company’s emphasis on detecting early retinal changes that may indicate future ocular or systemic disease.
RetinalGenix also issues news about collaborations and partnerships. These include agreements with a large laboratory services organization to support its DNA/RNA/GPS platform, a proteomics company to explore novel biomarkers, and a genetic research company to integrate advanced retinal imaging with clinical-grade DNA genotyping. Such announcements describe goals like developing predictive models, enabling population-level screening, and correlating retinal and genetic biomarkers.
Additional news items cover therapeutic research, laboratory infrastructure, and advisory appointments in pharmacogenetics and precision medicine. Investors and observers following RTGN news can expect updates on investigational device development, clinical study planning, biomarker discovery collaborations, patent portfolio expansion, and R&D activities related to early detection and treatment of eye and systemic diseases.
For those tracking RTGN, this news stream offers insight into how the company presents its scientific strategy, partnerships, and progress across retinal imaging, genetics, and therapeutics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
RetinalGeniX Technologies (RTGN) will present at the Emerging Growth Conference on October 26, 2022, at 1:00 PM Eastern. The 30-minute presentation will be led by Jerry Katzman, the company's CEO, highlighting its mission to prevent blindness through innovative retinal screening and home monitoring. Additionally, the company aims to diagnose systemic diseases, including heart disease and Alzheimer’s, via genetic mapping. Attendees can register for live participation or access an archived webcast post-event.
RetinalGenix Technologies (OTCQB:RTGN) announced the appointment of Dr. Vinay Mehindru to its Board of Directors, aimed at enhancing initiatives for population health management and supporting the company's planned upgrade from OTCBQB to NASDAQ.
Dr. Mehindru brings over 25 years of healthcare expertise, holding leadership roles that integrate clinical and financial operations. His experience includes serving as Chief Medical Officer and building extensive physician networks.
RetinalGenix anticipates his contributions will improve the efficiency and effectiveness of its health screening technologies.
RetinalGeniX Technologies has acquired DNA/GPS Inc., a pharmacogenetics firm, enhancing its capabilities in retinal imaging and genetic mapping. This acquisition aims to revolutionize the diagnosis of systemic diseases like heart disease and Alzheimer’s by allowing healthcare providers to conduct tests at primary care centers, significantly reducing costs compared to traditional methods. The platform is expected to enable early detection and interventions, focusing on patients with genetic predispositions to various diseases, with industry expertise led by Dr. Larry Perich.
RetinalGeniX Technologies, Inc. (OTCQB: RTGN) has officially commenced trading on the OTCQB Venture Market. The company's mission focuses on preventing blindness through high-resolution retinal screening and patient home monitoring. It has launched two innovative products: the RetinalCam™ Home Monitoring System for real-time access, and the RetinalGeniX Imaging System (RIS) for affordable retinal screening without dilation. With diabetes affecting millions and an anticipated increase in cases, RetinalGeniX aims to address the shortage of eyecare professionals and enhance telehealth capabilities.